Deals channel feed

Es­pe­ri­on's strug­gling-to-mar­ket, would-be block­buster finds fresh in­fu­sion of cash

5 years ago

The Car­lyle Group shells out $435M for con­trol­ling stake in vac­cine, gene ther­a­py ser­vices com­pa­ny

5 years ago

As Mod­er­na rose, Flag­ship cashed in for $1.4B — with a lot more wealth still re­main­ing

5 years ago

Ver­tex adds a new gene edit­ing part­ner, pay­ing Ob­sid­i­an $75M for con­trol­lable CRISPR sys­tem

5 years ago

Ver­tex pays CRISPR $900M to take con­trol of sick­le cell part­ner­ship, bet­ting they can beat blue­bird -- and re­new­ing an­a­lyst­s' skep­ti­cism

5 years ago

Kazia swipes an ex-Sanofi mol­e­cule for £1M up­front as they look to repli­cate their Genen­tech snag

5 years ago

Q1: A flood of in­vestor cash drove biotech's num­bers to new record highs, and the tor­rent of cash is mov­ing up­stream fast

5 years ago

As­traZeneca-Alex­ion merg­er slides through FTC re­view af­ter sup­posed M&A crack­down pos­es no bar­ri­ers

5 years ago
Pharma

In one of their first ever ac­qui­si­tions, Re­lay bets $85M cash on a new AI-based screen­ing ap­proach

5 years ago

An­oth­er big CRO deal has land­ed as Ther­mo Fish­er ac­quires PPD for $17.4B

5 years ago

An­ti-ag­ing biotech up­start plucks a drug from Am­gen's dis­card pile, piv­ot­ing from heart fail­ure to mus­cle con­di­tions

5 years ago

Eli Lil­ly seeds a well-con­nect­ed Chi­na neu­ro start­up with drugs aim­ing at where Bio­gen, Voy­ager missed

5 years ago
China

Af­ter be­ing goad­ed to sell the com­pa­ny, Alex­ion's CEO set some am­bi­tious new goals for in­vestors. Then Pas­cal So­ri­ot came call­ing

5 years ago

Tim Lu’s gene-cir­cuit star Sen­ti signs up for a $645M dis­cov­ery al­liance with Roche sub Spark

5 years ago

Neil Ku­mar's Bridge­Bio finds 7 new aca­d­e­m­ic part­ners to join the fight against ge­net­ic dis­ease

5 years ago

End­points ex­clu­sive: Bob Nelsen's Re­silience snags Flori­da CD­MO work­ing with the De­fense De­part­ment on Covid-19 an­ti­body

5 years ago

Sanofi teams with vir­tu­al re­al­i­ty biotech on oral Dupix­ent suc­ces­sor

5 years ago
Discovery

Sanofi un­veils $476M vac­cine plant in Sin­ga­pore, bring­ing its to­tal out­lay to $1.7B in the field for past year

5 years ago
Manufacturing

Taysha Gene Ther­a­pies gears up to ap­proach reg­u­la­tors with a new can­di­date for a de­bil­i­tat­ing neu­rode­gen­er­a­tive dis­ease

5 years ago
Cell/Gene Tx

Sanofi CEO Paul Hud­son dives deep­er in­to mR­NA, buy­ing out an un­der-the-radar Fred Hutch spin­out

5 years ago

CD­MO Ster­ling ac­quires ADC Bio, ramp­ing up ca­pac­i­ty for an­ti­body-drug con­ju­gate man­u­fac­tur­ing work

5 years ago
Manufacturing

No­var­tis taps DNA dam­age spe­cial­ist Ar­tios in $1.3B dis­cov­ery deal to com­ple­ment grow­ing ra­di­oli­gand port­fo­lio

5 years ago
Discovery

Catal­ent pledges to in­crease pro­duc­tion of Mod­er­na vac­cine at its In­di­ana fill-fin­ish plant

5 years ago
Manufacturing

Af­ter No­var­tis walks on last STING drug, Chi­nook spits out or­phan Aduro as­sets

5 years ago
First page Previous page 76777879808182 Next page Last page
A service from the Financial Times